A day after executing a reverse stock split to maintain its Nasdaq listing, Enveric Biosciences (NASDAQ: ENVB) raised $5 million Thursday through a public offering, sending its newly consolidated shares sharply lower.
The company priced 1.67 million shares at $3 each, well below the $3.90 split-adjusted closing price Thursday. The stock…
Please login to read all 248 words.
